Mosenzon, O <br/><br/>
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.  [electronic resource] 

 -  Diabetes/metabolism research and reviews  Jul 2013 
 - 417-26 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1520-7560 
<br/><br/><label>Standard No.: </label>10.1002/dmrr.2413  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--adverse effects<br/>Aged<br/>Biomarkers--blood<br/>Body Mass Index<br/>Cardiovascular Diseases--chemically induced<br/>Diabetes Mellitus, Type 2--blood<br/>Diabetic Angiopathies--epidemiology<br/>Diabetic Nephropathies--epidemiology<br/>Dipeptides--adverse effects<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Humans<br/>Hyperglycemia--epidemiology<br/>Hypoglycemic Agents--adverse effects<br/>Insulin Resistance<br/>Male<br/>Middle Aged<br/>Overweight--complications<br/>Prevalence<br/>Risk Factors<br/>Severity of Illness Index